The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II study of eribulin with trasutuzumab for pretreated locally advanced or metastatic HER2-positive breast cancer.
 
Nobuyuki Tsunoda
Honoraria - AstraZeneca Japan; Chugai Pharma; Eisai; Novartis
 
Masaya Hattori
Honoraria - AstraZeneca Japan; Chugai Pharma; Eisai; Novartis
 
Toru Murata
No Relationships to Disclose
 
Kazuhisa Akahane
No Relationships to Disclose
 
Keitaro Kamei
No Relationships to Disclose
 
Yasutomo Goto
No Relationships to Disclose
 
Takeshi Amemiya
No Relationships to Disclose
 
Kazumi Nishimae
No Relationships to Disclose
 
Tomoyuki Kubota
No Relationships to Disclose
 
Yuko Ito
No Relationships to Disclose
 
Yasuhiro Kurumiya
No Relationships to Disclose
 
Motoi Yoshihara
No Relationships to Disclose
 
Kenichi Nakanishi
No Relationships to Disclose
 
Toyone Kikumori
No Relationships to Disclose
 
Masahiko Ando
No Relationships to Disclose
 
Masato Nagino
No Relationships to Disclose